Cargando…

Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis

AIMS: Cardiac resynchronization therapy (CRT) is highly effective in dilated cardiomyopathy (DCM) patients with impaired left ventricular ejection fraction (LVEF) and left bundle block branch. In cardiac amyloidosis (CA) patients, left ventricular dysfunction and conduction defects are common, but t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fischer, Kilian, Lellouche, Nicolas, Damy, Thibaud, Martins, Raphaël, Clementy, Nicolas, Bisson, Arnaud, Lesaffre, François, Espinosa, Madeline, Garcia, Rodrigue, Degand, Bruno, Serzian, Guillaume, Jourda, François, Huttin, Olivier, Guichard, Jean‐Baptiste, Devilliers, Hervé, Eicher, Jean‐Christophe, Laurent, Gabriel, Guenancia, Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787999/ https://www.ncbi.nlm.nih.gov/pubmed/34734471 http://dx.doi.org/10.1002/ehf2.13663

Ejemplares similares

Deleterious effect of right ventricular pacing in patients with cardiac transthyretin amyloidosis: potential clinical benefit of cardiac resynchronization therapy
por: Aouate, David, et al.
Publicado: (2020)

Galectin-3 predicts response and outcomes after cardiac resynchronization therapy
por: Andre, Clémentine, et al.
Publicado: (2018)

Cardiac Resynchronization Therapy for Transthyretin Cardiac Amyloidosis
por: Donnellan, Eoin, et al.
Publicado: (2020)

Posterior longitudinal strain by speckle tracking echocardiography, marker of cardiac amyloidosis?
por: Ternacle, Julien, et al.
Publicado: (2015)

Comparison and identification of early clinical, biological and echocardiographic prognostic markers in cardiac amyloidosis
por: Damy, Thibaud, et al.
Publicado: (2015)

Localization of Left Ventricular Lead Electrodes in Relation to Myocardial Scar in Patients Undergoing Cardiac Resynchronization Therapy
por: Bisson, Arnaud, et al.
Publicado: (2018)

Electrical cardioversion of atrial arrhythmias with cardiac amyloidosis in the era of direct oral anticogulants
por: Touboul, Olivier, et al.
Publicado: (2022)

Left ventricular and atrial function in systemic light chains amyloidosis: an echocardiography and cardiac magnetic resonance comparison
por: Mohty, Dania, et al.
Publicado: (2015)

Impact of cardiac resynchronization therapy optimization inside a heart failure programme: a real‐world experience
por: Moulin, Thibaut, et al.
Publicado: (2022)

Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis
por: Ridouani, Fourat, et al.
Publicado: (2018)

Successful ‘quadrangular' pacing in a non-responder patient to cardiac resynchronization therapy
por: Clementy, Nicolas, et al.
Publicado: (2011)

Frailty in Wild-Type Transthyretin Cardiac Amyloidosis: The Tip of the Iceberg
por: Broussier, Amaury, et al.
Publicado: (2021)

Cardiac resynchronization therapy via left bundle branch area pacing and a dual-chamber ICD; a CROSS-LEFT substudy
por: Clementy, N, et al.
Publicado: (2023)

Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature
por: Adam, Robert Daniel, et al.
Publicado: (2021)

Usefulness of 99mTc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis
por: Galat, Arnault, et al.
Publicado: (2015)

History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis
por: Kharoubi, Mounira, et al.
Publicado: (2021)

Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis – Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)
por: Kristen, Arnt V., et al.
Publicado: (2017)

Echocardiographic Patterns of Left Ventricular Diastolic Function in Cardiac Amyloidosis: An Updated Evaluation
por: Oghina, Silvia, et al.
Publicado: (2021)

Prevalence and determinants of iron deficiency in cardiac amyloidosis
por: Jobbé‐Duval, Antoine, et al.
Publicado: (2022)

Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Damy, Thibaud, et al.
Publicado: (2019)

Transthyretin cardiac amyloidosis in Saudi Arabia and the Middle East: insights, projected prevalence and practical applications
por: Mohty, Dania, et al.
Publicado: (2023)

DISCOVERY: a study examining the prevalence of transthyretin mutations in subjects suspected of having cardiac amyloidosis
por: Akinboboye, Olakunle, et al.
Publicado: (2015)

Patients with cardiac amyloidosis are at a greater risk of mortality and hospital readmission after acute heart failure
por: Berthelot, Emmanuelle, et al.
Publicado: (2023)

Perioperative ventilatory strategies in cardiac surgery
por: Lellouche, François, et al.
Publicado: (2015)

High Risk of Sustained Ventricular Arrhythmia Recurrence After Acute Myocarditis
por: Rosier, Laurent, et al.
Publicado: (2020)

T-wave oversensing due to left ventricle–only pacing in cardiac resynchronization therapy optimization algorithm
por: André, Philippe, et al.
Publicado: (2018)

Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study
por: Garcia, Rodrigue, et al.
Publicado: (2020)

Dexamethasone is associated with early deaths in light chain amyloidosis patients with severe cardiac involvement
por: Bézard, Mélanie, et al.
Publicado: (2021)

Prevalence and prognostic value of autonomic neuropathy assessed by Sudoscan® in transthyretin wild‐type cardiac amyloidosis
por: Kharoubi, Mounira, et al.
Publicado: (2020)

Intracardiac Thrombosis and Heart Failure in a Patient with Hepatocellular Carcinoma and Cardiac Amyloidosis and an Implanted Cardiac Resynchronization Therapy Device
por: Akutsu, Yasushi, et al.
Publicado: (2019)

Incidence of atrial fibrillation in cryptogenic stroke with patent foramen ovale closure: protocol for the prospective, observational PFO-AF study
por: Badoz, Marc, et al.
Publicado: (2023)

Cardiac resynchronization therapy in heart failure patients with atrial fibrillation
por: Gasparini, Maurizio, et al.
Publicado: (2009)

Characteristics and natural history of early-stage cardiac transthyretin amyloidosis
por: Law, Steven, et al.
Publicado: (2022)

Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study
por: Nicol, Martin, et al.
Publicado: (2023)

Usefulness of NT-pro BNP monitoring to identify echocardiographic responders following cardiac resynchronization therapy
por: Magne, Julien, et al.
Publicado: (2009)

Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms
por: Gonzalez-Lopez, Esther, et al.
Publicado: (2022)

Cardiac Findings and Events Observed in an Open-Label Clinical Trial of Tafamidis in Patients with non-Val30Met and non-Val122Ile Hereditary Transthyretin Amyloidosis
por: Damy, Thibaud, et al.
Publicado: (2015)

Evaluation of a new ELISA assay for monoclonal free‐light chain detection in patients with cardiac amyloidosis
por: Abroud, Hajer, et al.
Publicado: (2022)

Cardiac Resynchronization Therapy in Children
por: Batra, Anjan S, et al.
Publicado: (2009)

Advances in Cardiac Resynchronization Therapy
por: Jafferani, Asif, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d4ngkvhfogj5mrt1354j9lmrt2